Literature DB >> 7461025

Desipramine and 2-hydroxy-desipramine pharmacokinetics in normal volunteers.

C L DeVane, M Savett, W J Jusko.   

Abstract

Disposition characteristics of desipramine and its metabolite, 2-hydroxy-desipramine, were determined in four healthy male volunteers following an oral 50 mg dose of desipramine. Nonlinear least-squares regression of concentration-time data indicated that parent drug disposition could be described by a one-compartment open pharmacokinetic model for two subjects and by a two-compartment model for two subjects. The early appearance of 2-hydroxy-desipramine and its high peak concentrations indicates that desipramine probably undergoes pre-systemic elimination partly through formation of 2-hydroxy-desipramine. The substantial production of 2-hydroxy-desipramine, as reflected by the area under its concentration-time curve which was 51% to 94% of that for desipramine, indicates that accumulation will occur following multiple dosing. As 2-hydroxy-desipramine may possess antidepressant activity, future studies designed to assess the therapeutic effect of desipramine should account for the presence of its pharmacologically active metabolite.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7461025     DOI: 10.1007/bf00558386

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  14 in total

1.  Comparison of observed and predicted bioavailability of nortriptyline in humans following oral administration.

Authors:  M Gibaldi
Journal:  J Pharm Sci       Date:  1975-06       Impact factor: 3.534

2.  Desipramine plasma levels and clinical response in depressed outpatients.

Authors:  R O Friedel; R C Veith; V Bloom; R J Bielski
Journal:  Commun Psychopharmacol       Date:  1979

3.  Desipramine plasma levels and therapeutic response.

Authors:  R Khalid; M M Amin; T A Ban
Journal:  Psychopharmacol Bull       Date:  1978-01

4.  High-performance liquid chromatographic assay for imipramine, desipramine, and their 2-hydroxylated metabolites.

Authors:  T A Sutfin; W J Jusko
Journal:  J Pharm Sci       Date:  1979-06       Impact factor: 3.534

5.  Studies of C-14-protriptyline man: plasma levels and excretion.

Authors:  K D Charalampous; P C Johnson
Journal:  J Clin Pharmacol J New Drugs       Date:  1967 Mar-Apr

6.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

7.  Hydroxylated metabolites of tricyclic antidepressants: preclinical assessment of activity.

Authors:  W Z Potter; H M Calil; A A Manian; A P Zavadil; F K Goodwin
Journal:  Biol Psychiatry       Date:  1979-08       Impact factor: 13.382

8.  Plasma protein binding of basic drugs. I. Selective displacement from alpha 1-acid glycoprotein by tris(2-butoxyethyl) phosphate.

Authors:  O Borgå; K M Piafsky; O G Nilsen
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

9.  First-pass metabolism of imipramine in man.

Authors:  L F Gram; J Christiansen
Journal:  Clin Pharmacol Ther       Date:  1975-05       Impact factor: 6.875

10.  Inhibition of biogenic amines uptake by imipramine, desipramine, 2 OH-imipramine and 2 OH-desipramine in rat brain.

Authors:  J I Javaid; J M Perel; J M Davis
Journal:  Life Sci       Date:  1979-01-01       Impact factor: 5.037

View more
  11 in total

1.  Drug pharmacokinetics and the carbon dioxide breath test.

Authors:  E A Lane; I Parashos
Journal:  J Pharmacokinet Biopharm       Date:  1986-02

Review 2.  Pharmacokinetic optimisation of tricyclic antidepressant therapy.

Authors:  M Furlanut; P Benetello; E Spina
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

3.  Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials.

Authors:  Ivelina Gueorguieva; Kimberley Jackson; Steven A Wrighton; Vikram P Sinha; Jenny Y Chien
Journal:  Br J Clin Pharmacol       Date:  2010-10       Impact factor: 4.335

Review 4.  Clinical pharmacokinetics of imipramine and desipramine.

Authors:  F R Sallee; B G Pollock
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

5.  The analysis and disposition of imipramine and its active metabolites in man.

Authors:  T A Sutfin; C L DeVane; W J Jusko
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

6.  Cerebral and blood pharmacokinetics of imipramine and its active metabolites in the pregnant rat.

Authors:  C L DeVane; J W Simpkins; S A Stout
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

7.  Desipramine pharmacokinetics in Chinese and Caucasian volunteers.

Authors:  M V Rudorfer; E A Lane; W H Chang; M D Zhang; W Z Potter
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

8.  Pharmacological properties of the active metabolites of the antidepressants desipramine and citalopram.

Authors:  Jean D Deupree; Megan D Montgomery; David B Bylund
Journal:  Eur J Pharmacol       Date:  2007-08-23       Impact factor: 4.432

Review 9.  Metabolism of tricyclic antidepressants.

Authors:  M V Rudorfer; W Z Potter
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

10.  Development and Qualification of Physiologically Based Pharmacokinetic Models for Drugs With Atypical Distribution Behavior: A Desipramine Case Study.

Authors:  T S Samant; V Lukacova; S Schmidt
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.